Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn’s Disease

Tofacitinib in the Treatment of Crohn's-Like Disease of the Pouch

(2020) Christina M. Bauer et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

(2019) Tamara Pérez-Jeldres et al.   Frontiers in Pharmacology

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

(2019) William J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

JAK efficacy in Crohn’s disease

(2019) Gerhard Rogler   Journal of Crohns & Colitis

904 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 4.4 Years of Safety Data from Global Clinical Trials

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort

(2010) Kelvin T. Thia et al.   GASTROENTEROLOGY